Erlotinib as second- or third-line treatment in elderly patients with advanced non-small cell lung cancer: Keio Lung Oncology Group Study 001 (KLOG001)Masayoshi Miyawaki, Kenzo Soejima, Sohei Nakayama et al.|Molecular and Clinical Oncology|2017Cited by 10
Clinical Outcomes of Later‐Generation <scp>EGFR</scp> ‐ <scp>TKIs</scp> for Uncommon <scp>EGFR</scp> Mutations in <scp>NSCLC</scp> : A Multicenter Real‐World StudyLisa Shigematsu, Tetsuo Tani, Shinnosuke Ikemura et al.|Thoracic Cancer|2025Cited by 0